RECRUITING

Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study that will be enrolling University of Louisville patients who present to the Emergency Department in Acute Respiratory Failure. This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.

Official Title

Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)

Quick Facts

Study Start:2021-09-09
Study Completion:2024-08-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05144633

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults aged 18 years or older presenting to the ED or admitted to the hospital within 12 hours of enrollment
  2. * Acute respiratory failure defined as new onset shortness of breath initiated within the last 7 days, and new or increasing need for oxygen therapy
  3. * The patient or patient's legal health care proxy consents to participation
  1. * Patients with trauma as the cause of ARF
  2. * Patients with pneumothorax as the cause of ARF
  3. * Inability to perform pulmonary POCUS or lung auscultation (e.g. dressing on the chest)
  4. * Unwilling or unable to complete the minimum of 12 lung sound stethoscope recordings.

Contacts and Locations

Study Contact

Andrea M Reyes Vega, M.D.
CONTACT
5028528884
a0reye02@louisville.edu
Rodrigo Cavallazzi, M.D.
CONTACT
rodrigo.cavallazzi@louisville.edu

Principal Investigator

Rodrigo Cavallazzi, MD
PRINCIPAL_INVESTIGATOR
University of Louisville

Study Locations (Sites)

University of Louisville
Louisville, Kentucky, 40202
United States

Collaborators and Investigators

Sponsor: University of Louisville

  • Rodrigo Cavallazzi, MD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-09
Study Completion Date2024-08-30

Study Record Updates

Study Start Date2021-09-09
Study Completion Date2024-08-30

Terms related to this study

Additional Relevant MeSH Terms

  • Acute Respiratory Failure